Top

Journal of Assisted Reproduction and Genetics

Published in:

01-07-2016 | Reproductive Physiology and Disease

Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome

Authors: BiJun Wang, MengMeng Hao, QingLing Yang, Jing Li, YiHong Guo

Published in: Journal of Assisted Reproduction and Genetics | Issue 7/2016

Abstract

Purpose

To explore the relationships between the soluble receptor for advanced glycation endproducts (sRAGE) and the outcome parameters following in vitro fertilization-embryo transfer (IVF-ET) in patients with polycystic ovary syndrome (PCOS) and investigate the protective effect of sRAGE in PCOS development regarding inflammation.

Methods

We conducted a prospective analysis of a subsample of 74 participants from the Reproductive Medical Center of the First Affiliated Hospital of Zhengzhou University. We quantified sRAGE, vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-α), interleukelin-6 (IL-6), and C-reactive protein (CPR) protein levels in the follicular fluid from 39 PCOS and 35 non-PCOS reproductive-age women. sRAGE and VEGF, TNF-α, IL-6, and CRP in follicular fluid aspirated without blood were measured by ELISA.

Results

sRAGE concentrations in the follicular fluid were significantly lower in the PCOS group compared to those in the control group, while VEGF, TNF-α, IL-6, and CRP concentrations were significantly higher in the PCOS group than in the control group (P < 0.05). sRAGE was significantly, inversely correlated with the total dose of gonadotropin (Gn) in the PCOS group undergoing IVF treatment (r = −0.451, P = 0.004). After adjusting for age and Gn dose (in international units used per cycle), sRAGE protein levels in the follicular fluid were significantly, inversely related to VEGF (r = −0.378, P = 0.018), TNF-α (r = −0.450, P = 0.004), IL-6 (r = −0.455, P = 0.004), and CRP (r = −0.375, P = 0.019).

Conclusion

sRAGE in the follicular fluid might exert a protective effect against the inflammatory action of PCOS development.

Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage. J Clin Endocrinol Metab. 2015;100(3):911–9. doi:10.1210/jc.2014-3886.CrossRefPubMed

Liu M, Gao J, Zhang Y, Li P, Wang H, Ren X, et al. Serum levels of TSP-1, NF-kappaB and TGF-beta1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation. Clin Endocrinol. 2015;83(6):913–22. doi:10.1111/cen.12951.CrossRef

Pertynska-Marczewska M, Diamanti-Kandarakis E, Zhang J, Merhi Z. Advanced glycation end products: a link between metabolic and endothelial dysfunction in polycystic ovary syndrome? Metab Clin Exp. 2015;64(11):1564–73. doi:10.1016/j.metabol.2015.08.010.CrossRefPubMed

Hu H, Jiang H, Ren H, Hu X, Wang X, Han C. AGEs and chronic subclinical inflammation in diabetes: disorders of immune system. Diabetes Metab Res Rev. 2015;31(2):127–37. doi:10.1002/dmrr.2560.CrossRefPubMed

Palimeri S, Palioura E, Diamanti-Kandarakis E. Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management. Diabetes, Metab Syndr Obes: Targets Ther. 2015;8:415–26. doi:10.2147/dmso.s63089.

Wang YS, Li YY, Wang LH, Kang Y, Zhang J, Liu ZQ, et al. Tanshinone IIA attenuates chronic pancreatitis-induced pain in rats via downregulation of HMGB1 and TRL4 expression in the spinal cord. Pain Physician. 2015;18(4):E615–28.PubMed

Lazo M, Halushka MK, Shen L, Maruthur N, Rebholz CM, Rawlings AM, et al. Soluble receptor for advanced glycation end products and the risk for incident heart failure: the atherosclerosis risk in communities study. Am Heart J. 2015;170(5):961–7. doi:10.1016/j.ahj.2015.08.008.CrossRefPubMed

Merhi Z. Advanced glycation end products and their relevance in female reproduction. Human reproduction (Oxford, England). 2014; 29(1): 135–45. doi:10.1093/humrep/det383.

Romero R, Espinoza J, Hassan S, Gotsch F, Kusanovic JP, Avila C, et al. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation. J Perinat Med. 2008;36(5):388–98. doi:10.1515/jpm.2008.076.CrossRefPubMed

10.

Rzepka R, Dolegowska B, Rajewska A, Kwiatkowski S, Salata D, Budkowska M, et al. Soluble and endogenous secretory receptors for advanced glycation end products in threatened preterm labor and preterm premature rupture of fetal membranes. BioMed Res Int. 2015;2015:568042. doi:10.1155/2015/568042.CrossRefPubMedPubMedCentral

11.

Merhi Z, Irani M, Doswell AD, Ambroggio J. Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. J Clin Endocrinol Metab. 2014;99(2):E226–33. doi:10.1210/jc.2013-3839.CrossRefPubMed

12.

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction (Oxford, England). 2004; 19(1): 41–7.

13.

Wu TL, Tsai CC, Wang YY, Ho KY, Wu YM, Hung HC, et al. The association between the RAGE G82S polymorphism, sRAGE and chronic periodontitis in Taiwanese individuals with and without diabetes. J Periodontal Res. 2015;50(6):881–9. doi:10.1111/jre.12282.CrossRefPubMed

14.

Sharma I, Dhawan V, Saha SC, Rashmi B, Dhaliwal LK. Implication of the RAGE-EN-RAGE axis in endometriosis. Int J Gynaecol Obstet: Off Organ Int Fed Gynaecol Obstet. 2010;110(3):199–202. doi:10.1016/j.ijgo.2010.03.037.CrossRef

15.

Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front biosci (Elite edition). 2010;2:1184–95.CrossRef

16.

Lee EJ, Park EY, Mun H, Chang E, Ko JY, do Kim Y, et al. Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation. FASEB J: Off Publ Fed Am Soc Exp Biol. 2015;29(8):3506–14. doi:10.1096/fj.15-272302.CrossRef

17.

He CT, Lee CH, Hsieh CH, Hsiao FC. Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents. Int J Endocrinol. 2014;2014:657607. doi:10.1155/2014/657607.PubMedPubMedCentral

18.

Gonzalez F. Nutrient-induced inflammation in polycystic ovary syndrome: role in the development of metabolic aberration and ovarian dysfunction. Semin Reprod Med. 2015;33(4):276–86. doi:10.1055/s-0035-1554918.CrossRefPubMed

19.

Peluso C, Fonseca FL, Rodart IF, Cavalcanti V, Gastaldo G, Christofolini DM, et al. AMH: an ovarian reserve biomarker in assisted reproduction. Clin Chim Acta: Int J Clin Chem. 2014;437:175–82. doi:10.1016/j.cca.2014.07.029.CrossRef

20.

Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril. 2014;102(2):460–8.e3. doi:10.1016/j.fertnstert.2014.04.046.CrossRefPubMed

21.

Bonetti TC, Borges Jr E, Braga DP, Iaconelli Jr A, Kleine JP, Silva ID. Intrafollicular soluble receptor for advanced glycation end products (sRAGE) and embryo quality in assisted reproduction. Reprod Biomed Online. 2013;26(1):62–7. doi:10.1016/j.rbmo.2012.10.001.CrossRefPubMed

22.

Guclu M, Ali A, Eroglu DU, Buyukuysal SO, Cander S, Ocak N. Serum levels of sRAGE are associated with body measurements, but not glycemic parameters in patients with prediabetes. Metab Syndr Relat Disord. 2016;14(1):33–9. doi:10.1089/met.2015.0078.CrossRefPubMed

23.

Uribarri J, del Castillo MD, de la Maza MP, Filip R, Gugliucci A, Luevano-Contreras C et al. Dietary advanced glycation end products and their role in health and disease. 2015.

24.

Schmidt AM. Soluble RAGEs—prospects for treating & tracking metabolic and inflammatory disease. Vasc Pharmacol. 2015;72:1–8. doi:10.1016/j.vph.2015.06.011.CrossRef

25.

Stewart C, Cha S, Caudle RM, Berg K, Katz J. Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjogren’s syndrome. Rheumatol Int. 2008;28(8):771–6. doi:10.1007/s00296-008-0529-4.CrossRefPubMed

26.

Chen CG, Tang P, Yu ZT. Effect of HMGB1 on the VEGF-C expression and proliferation of esophageal squamous cancer cells. Zhonghua zhong liu za zhi Chin J Oncol. 2012;34(8):566–70. doi:10.3760/cma.j.issn.0253-3766.2012.08.002.

27.

Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol. 2001;159(2):513–25. doi:10.1016/s0002-9440(10)61723-3.CrossRefPubMedPubMedCentral

28.

Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reprod Biol Endocrinol: RB&E. 2014;12:82. doi:10.1186/1477-7827-12-82.CrossRef

29.

Manau D, Balasch J, Jimenez W, Fabregues F, Civico S, Casamitjana R, et al. Follicular fluid concentrations of adrenomedullin, vascular endothelial growth factor and nitric oxide in IVF cycles: relationship to ovarian response. Hum Reprod (Oxford, England). 2000;15(6):1295–9.CrossRef

30.

Wu R, Van der Hoek KH, Ryan NK, Norman RJ, Robker RL. Macrophage contributions to ovarian function. Hum Reprod Update. 2004;10(2):119–33. doi:10.1093/humupd/dmh011.CrossRefPubMed

31.

Gonzalez F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77(4):300–5. doi:10.1016/j.steroids.2011.12.003.CrossRefPubMed

32.

Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048–58.e1-2. doi:10.1016/j.fertnstert.2010.11.036.CrossRefPubMed

33.

Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, Qu W, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med. 2005;201(3):473–84. doi:10.1084/jem.20040934.CrossRefPubMedPubMedCentral

34.

Malickova K, Jarosova R, Rezabek K, Fait T, Masata J, Janatkova I, et al. Concentrations of sRAGE in serum and follicular fluid in assisted reproductive cycles—a preliminary study. Clin Lab. 2010;56(9–10):377–84.PubMed

Title: Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome
Authors: BiJun Wang
MengMeng Hao
QingLing Yang
Jing Li
YiHong Guo
Publication date: 01-07-2016
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 7/2016
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-016-0704-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2016

On the dichotomy (im)posed by developmental autonomy during early human embryogenesis

Association of interleukin-10 gene promoter polymorphisms with recurrent pregnancy loss: a meta-analysis

The PlA2 variant of the platelet glycoprotein IIIa as a genetic risk factor for IVF implantation failure: accumulating evidence

The endometrial preparation for frozen-thawed euploid blastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist

Immunogenetic contributions to recurrent pregnancy loss

Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis